See more : Nexa Resources S.A. (NEXA.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Intra-Cellular Therapies, Inc. (ITCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intra-Cellular Therapies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Sungold Media and Entertainmen (SMEL.BO) Income Statement Analysis – Financial Results
- Auto Trader Group plc (ATDRF) Income Statement Analysis – Financial Results
- Cambridge Bancorp (CATC) Income Statement Analysis – Financial Results
- Nouveau Holdings, Ltd. (NHLI) Income Statement Analysis – Financial Results
- Cardinal Health, Inc. (CAH) Income Statement Analysis – Financial Results
Intra-Cellular Therapies, Inc. (ITCI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.37M | 249.13M | 81.71M | 22.53M | 60.61K | 0.00 | 245.84K | 330.70K | 91.36K | 577.30K | 2.74M | 3.12M |
| Cost of Revenue | 33.75M | 20.44M | 8.03M | 1.90M | 477.12K | 368.67K | 79.42M | 93.83M | 139.63K | 21.23M | 23.03M | 15.49M |
| Gross Profit | 430.63M | 228.69M | 73.67M | 20.64M | -416.51K | -368.67K | -79.17M | -93.50M | -48.26K | -20.65M | -20.29M | -12.37M |
| Gross Profit Ratio | 92.73% | 91.79% | 90.17% | 91.59% | -687.16% | 0.00% | -32,205.56% | -28,273.44% | -52.82% | -3,576.82% | -741.34% | -396.68% |
| Research & Development | 180.14M | 134.72M | 88.85M | 65.78M | 89.12M | 132.17M | 79.42M | 93.83M | 87.72M | 21.23M | 23.03M | 15.49M |
| General & Administrative | 317.66M | 272.98M | 190.11M | 150.06M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Selling & Marketing | 92.20M | 85.80M | 82.50M | 36.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 409.86M | 358.78M | 272.61M | 186.36M | 64.95M | 30.10M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Other Expenses | 0.00 | -1.18M | -2.10M | -282.23K | 0.00 | 0.00 | -245.84K | -330.70K | -60.71K | -29.76K | 0.00 | 0.00 |
| Operating Expenses | 590.01M | 492.32M | 359.36M | 251.86M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Cost & Expenses | 623.75M | 512.76M | 367.40M | 253.76M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29.00M | 19.52M |
| Interest Income | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.94M | 1.02M | 303.94K | 29.62K | 39.00K |
| Interest Expense | 0.00 | 7.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.78K | 0.00 | 7.07K | 612.96K | 193.50K |
| Depreciation & Amortization | 528.00K | 656.00K | 533.36K | 528.12K | 477.12K | 368.67K | 213.87K | 196.87K | 139.63K | 25.48K | 23.25K | 47.75K |
| EBITDA | -158.85M | -262.97M | -285.16M | -230.70M | -153.53M | -161.90M | -102.63M | -115.13M | -104.65M | -30.66M | -26.21M | -16.32M |
| EBITDA Ratio | -34.21% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -40,203.17% | -34,872.43% | -115,815.85% | -5,314.87% | -957.76% | -523.31% |
| Operating Income | -159.38M | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M | -102.84M | -118.26M | -105.81M | -30.99M | -26.27M | -16.40M |
| Operating Income Ratio | -34.32% | -105.82% | -349.65% | -1,026.28% | -254,090.46% | 0.00% | -41,832.65% | -35,759.96% | -115,815.85% | -5,367.52% | -959.69% | -526.09% |
| Total Other Income/Expenses | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.90M | 1.02M | 296.86K | -583.35K | -154.50K |
| Income Before Tax | -139.04M | -256.25M | -284.12M | -226.99M | -147.72M | -155.13M | -98.83M | -115.36M | -104.79M | -30.69M | -26.85M | -16.56M |
| Income Before Tax Ratio | -29.94% | -102.86% | -347.73% | -1,007.48% | -243,711.05% | 0.00% | -40,203.17% | -34,883.55% | -114,696.75% | -5,316.09% | -981.01% | -531.04% |
| Income Tax Expense | 636.00K | 6.00K | 5.63K | 13.51K | 1.60K | 1.60K | -1.06M | 1.07M | 1.60K | 1.60K | 18.00K | 32.92K |
| Net Income | -139.67M | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M | -97.77M | -116.43M | -104.79M | -30.69M | -26.87M | -16.59M |
| Net Income Ratio | -30.08% | -102.86% | -347.73% | -1,007.54% | -243,713.69% | 0.00% | -39,771.64% | -35,205.79% | -114,698.50% | -5,316.37% | -981.67% | -532.10% |
| EPS | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EPS Diluted | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| Weighted Avg Shares Out | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.01M | 28.65M | 17.22M | 22.16M |
| Weighted Avg Shares Out (Dil) | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.07M | 28.65M | 17.26M | 22.16M |
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder. Positive MDD results represent another de-risking event for the drug and should open up another...
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has completed the sale of...
3 Biotech Stocks With Skyrocketing Potential: April 2024
Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.
Intra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten...
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten...
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achieved with statistical significance.
Source: https://incomestatements.info
Category: Stock Reports